Literature DB >> 1740934

The critical relationship of antibiotic dose and bacterial contamination in experimental infection.

M S Citak1, J I Cué, J C Peyton, M A Malangoni.   

Abstract

Even though the usefulness of prophylactic antimicrobial administration for potentially contaminated operations is widely accepted, infection continues to occur in a finite number of cases. This study examined whether potential infection due to an increasing bacterial inoculum can be prevented or controlled by increasing antimicrobial doses. In an initial set of experiments, Sprague-Dawley rats were given various doses of cefazolin (15, 30, 60, 120 mg/kg) intraperitoneally, then serum and tissue levels were quantified. Serum and tissue drug concentrations correlated with the dose given. In another set of experiments, rats were given doses of either 0, 30 (standard dose), 60, or 120 mg/kg of cefazolin 30 min prior to subcutaneous inoculation of various doses of Staphylococcus aureus. After 6 days, inoculum sites were examined for abscess formation and size. At low levels of contamination, increasing in antibiotic dose to 30, 60, and 120 mg/kg, abscess formation was eliminated at 50, 80, and 92% of inoculum sites, respectively. At moderate levels of contamination, abscesses formed at all inoculum sites, but abscess size was significantly smaller as the dose increased. When a high inoculum of S. aureus was given, large doses of antibiotics provided no additional benefit. These data suggest that the risk of infection in this model of experimental infection is significantly related to the size of the bacterial inoculum. Increasing the dose of an effective antimicrobial increases drug concentration at the site of contamination and reduces the risk of infection. Administration of higher doses of prophylactic antimicrobials may be more effective when larger amounts of bacterial contamination are anticipated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1740934     DOI: 10.1016/0022-4804(92)90292-8

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection.

Authors:  A Giacometti; O Cirioni; R Ghiselli; L Goffi; C Viticchi; F Mocchegiani; A Riva; F Orlando; V Saba; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Polycationic peptides as prophylactic agents against methicillin-susceptible or methicillin-resistant Staphylococcus epidermidis vascular graft infection.

Authors:  A Giacometti; O Cirioni; R Ghiselli; L Goffi; F Mocchegiani; A Riva; G Scalise; V Saba
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

3.  RNA III inhibiting peptide inhibits in vivo biofilm formation by drug-resistant Staphylococcus aureus.

Authors:  Andrea Giacometti; Oscar Cirioni; Yael Gov; Roberto Ghiselli; Maria Simona Del Prete; Federico Mocchegiani; Vittorio Saba; Fiorenza Orlando; Giorgio Scalise; Naomi Balaban; Giorgio Dell'Acqua
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

4.  Efficacy of quinupristin-dalfopristin in preventing vascular graft infection due to Staphylococcus epidermidis with intermediate resistance to glycopeptides.

Authors:  Andrea Giacometti; Oscar Cirioni; Roberto Ghiselli; Fiorenza Orlando; Federico Mocchegiani; Alessandra Riva; Maria Simona Del Prete; Vittorio Saba; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

5.  Lipid-based slow-release formulation of amikacin sulfate reduces foreign body-associated infections in mice.

Authors:  A A Roehrborn; J F Hansbrough; B Gualdoni; S Kim
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.